KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Debt to Equity (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Debt to Equity data on record, last reported at -$36.06 in Q4 2025.

  • For Q4 2025, Debt to Equity fell 74.58% year-over-year to -$36.06; the TTM value through Dec 2025 reached -$36.06, down 74.58%, while the annual FY2025 figure was -$36.06, 74.58% down from the prior year.
  • Debt to Equity reached -$36.06 in Q4 2025 per AMRX's latest filing, down from -$23.41 in the prior quarter.
  • Across five years, Debt to Equity topped out at $120.94 in Q4 2023 and bottomed at -$41.79 in Q2 2024.
  • Average Debt to Equity over 5 years is -$0.78, with a median of $0.34 recorded in 2022.
  • Peak YoY movement for Debt to Equity: skyrocketed 14701.45% in 2023, then tumbled 344.28% in 2024.
  • A 5-year view of Debt to Equity shows it stood at $7.43 in 2021, then skyrocketed by 91.72% to $14.25 in 2022, then surged by 748.62% to $120.94 in 2023, then crashed by 117.08% to -$20.65 in 2024, then tumbled by 74.58% to -$36.06 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were -$36.06 in Q4 2025, -$23.41 in Q3 2025, and -$21.65 in Q2 2025.